Evaluating noncancer effects of trichloroethylene: dosimetry, mode of action, and risk assessment.
about
Trichloroethylene health risks--state of the scienceIn silico toxicology: simulating interaction thresholds for human exposure to mixtures of trichloroethylene, tetrachloroethylene, and 1,1,1-trichloroethane.A consistent approach for the application of pharmacokinetic modeling in cancer and noncancer risk assessment.Structures of aminoacylase 3 in complex with acetylated substratesNeurotoxic and pharmacokinetic responses to trichloroethylene as a function of exposure scenario.Human variability and susceptibility to trichloroethyleneDevelopment of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment.Dose-response analyses of the carcinogenic effects of trichloroethylene in experimental animals.Interstrain differences in the liver effects of trichloroethylene in a multistrain panel of inbred miceIssues in the pharmacokinetics of trichloroethylene and its metabolites.Framework for evaluation of physiologically-based pharmacokinetic models for use in safety or risk assessment.Evaluation of physiologically based pharmacokinetic models in risk assessment: an example with perchloroethylene.Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine.Liquid chromatography electrospray ionization tandem mass spectrometry analysis method for simultaneous detection of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine.Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion.The impact of cytochrome P450 2E1-dependent metabolic variance on a risk-relevant pharmacokinetic outcome in humans.Using physiologically-based pharmacokinetic modeling to address nonlinear kinetics and changes in rodent physiology and metabolism due to aging and adaptation in deriving reference values for propylene glycol methyl ether and propylene glycol methylTrichloroethylene, trichloroacetic acid, and dichloroacetic acid: do they affect eye development in the Sprague-Dawley rat?
P2860
Q24671489-BF162B03-C92B-42E8-84D8-6D1E58515DB3Q24810937-63EF2B49-EFC6-4797-842D-B3BD0CD162EFQ24815444-290E1B5B-518D-4B68-A91C-E9395A215856Q27664897-9E37DF40-95E7-4A4E-B5BC-69D843DFF039Q30503509-2F3C8104-ADDF-41F3-A065-6C7A26C3F814Q33916686-4A66C2BE-8AFA-40CA-83FE-40FB52A2E72BQ33916714-073992F1-1272-4902-A856-0E2A18A1968FQ33916723-DDAB31EC-0714-48CF-A69C-DAC19479B176Q34601385-A3F7A76D-721C-4797-ADEF-B6D7E2FBEC6DQ35039326-138AC704-A823-4798-8D23-EC826654DF58Q36014859-84B3B2CA-302D-44FA-A5E6-5E947E770143Q36227567-2FA7994D-D910-47B0-B8D9-C92DCA7286C1Q37333030-793F5C59-BB9B-4FAF-BCF8-CCEE93FC17D1Q37396395-8698BFB9-09B6-4F2E-91CE-084DA2D73DCDQ37820451-B3BA8B42-CAC3-4341-9999-24A34498F214Q44671178-087EE6D4-5FB5-476B-A949-AC650CA9BA64Q46474160-DE7A8B23-BEDF-408D-90D4-80AB502A09FCQ48684594-3FDE1718-9D9F-4564-BC0B-D280DA85CB21
P2860
Evaluating noncancer effects of trichloroethylene: dosimetry, mode of action, and risk assessment.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
name
Evaluating noncancer effects o ...... f action, and risk assessment.
@ast
Evaluating noncancer effects o ...... f action, and risk assessment.
@en
type
label
Evaluating noncancer effects o ...... f action, and risk assessment.
@ast
Evaluating noncancer effects o ...... f action, and risk assessment.
@en
prefLabel
Evaluating noncancer effects o ...... f action, and risk assessment.
@ast
Evaluating noncancer effects o ...... f action, and risk assessment.
@en
P2860
P356
P1476
Evaluating noncancer effects o ...... f action, and risk assessment.
@en
P2093
Clewell HJ 3rd
P2860
P304
P356
10.1289/EHP.00108S2323
P478
108 Suppl 2
P577
2000-05-01T00:00:00Z